Neko Health, the Stockholm-based preventive health startup founded by Daniel Ek, has closed a $700 million Series C round, the company confirmed this week. The round values Neko at nearly $7 billion, roughly four times its $1.7 billion valuation from a $260 million Series B round in January 2025.
What the round funds
The new capital will back Neko’s first expansion outside Sweden and the UK, with a flagship clinic planned for New York later this year. The company has previously said the US market is central to its growth plans given demand for its preventive-care model.
How the scan works
Neko’s core product is a roughly 15-minute body scan performed in a booth equipped with dozens of sensors, capturing skin imagery, cardiovascular readings and blood biomarkers in a single visit. The company says it applies machine-learning models trained on its growing scan dataset to help flag anomalies, such as suspicious moles or irregular heart readings, which clinicians then review with the patient immediately after the scan. More than 100,000 people have completed a scan and over 350,000 have registered or booked an appointment, according to the company.
Who’s backing it
Lightspeed Venture Partners led the round alongside co-lead O.G. Venture Partners, with existing backers Atomico, General Catalyst and Lakestar returning. New investors include Meta chief executive Mark Zuckerberg and Priscilla Chan, tennis player Maria Sharapova, musician will.i.am, and OpenAI, according to people familiar with the round. “We believe this is one of the most important healthcare companies of our generation,” said Bejul Somaia of Lightspeed.
Neko was founded in 2018 by Ek, Spotify’s founder, and entrepreneur Hjalmar Nilsonne. The company has framed itself as a bet that AI-assisted diagnostics can make routine, comprehensive health screening fast and affordable enough for regular use, rather than reserved for expensive annual physicals.